BioTelemetry
- Company typePublic
- Founded1994
- HeadquartersMalvern, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
BioTelemetry firmographics
Firmographics- Name
- BioTelemetry
- Legal name
- BioTelemetry, Inc.
- Website
- https://gobio.com
- Company type
- Public
- Founded year
- 1994
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
BioTelemetry industry classification
Industry- Product category
- Remote Cardiac Diagnostics and Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where BioTelemetry is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioTelemetry business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Remote Cardiac Monitoring Services: Wearable heart monitors (MCOT patch, extended Holter) that detect and transmit abnormal heart rhythms wirelessly. Physician-prescribed monitoring services billed to insurance. Primary revenue driver representing 85% of sales.
- Centralized Core Laboratory Services: Clinical research business providing testing services for clinical trials. Serves pharmaceutical and biotech companies conducting clinical research.
- Remote Blood Glucose Monitoring: Remote patient monitoring platform for diabetes management. Includes On.Demand RPM platform acquired from Centene focusing on diabetes, hypertension, and chronic heart failure.
- Original Equipment Manufacturing: OEM manufacturing services serving both healthcare and clinical research customers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Insurance-based service billing |
| Subscription | Monthly | Remote INR Patient Self-Testing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
BioTelemetry product offering
Product offeringCore offering
BioTelemetry delivers remote cardiac monitoring and diagnostics services through FDA-cleared wearable devices (MCOT patch and ePatch Extended Holter) that capture and transmit ECG data for AI-powered arrhythmia detection, supplemented by Remote INR self-testing for anticoagulation management, Geneva Healthcare's implantable device monitoring platform, and BioTel Research core lab services for clinical trials. Services are physician-prescribed, processed through centralized monitoring centers, and delivered into major EMR systems for healthcare providers.
Product overview
BioTelemetry, a Philips company operating as Philips Ambulatory Monitoring and Diagnostics, offers a unified portfolio of remote cardiac diagnostics, monitoring, and patient management solutions. The core product suite is anchored by MCOT (Mobile Cardiac Outpatient Telemetry) — a flagship AI-powered wearable cardiac telemetry patch — and ePatch (Extended Holter) — a 3–14 day continuous ECG recording device. These are complemented by Remote INR for INR self-testing, a suite of Clinical Pathways (stroke, ED discharge, primary care, AF ablation, TAVR) that integrate MCOT and ePatch into specific care workflows, and an EMR Integration module that delivers reports directly into EPIC, Cerner, Allscripts, and other hospital systems. BioTelemetry also operates Geneva Healthcare (implantable device data management), BioTel Research (centralized core lab services for clinical trials), and manages the On.Demand chronic RPM platform for diabetes, hypertension, and heart failure coaching. Following Philips' USD 2.8 billion acquisition in February 2021, the portfolio is consolidated under the Philips Ambulatory Monitoring and Diagnostics brand while preserving the BioTelemetry, BioTel Heart, CardioNet, and Geneva Healthcare sub-brands.
Differentiator
Problem solved
Functional benefit
Brands
- MCOT (Mobile Cardiac Outpatient Telemetry): Mobile cardiac telemetry system for arrhythmia detection with FDA approval, featuring SmartDetect algorithm and up to 30 days of monitoring.
- ePatch
- Remote INR
- CardioKey
- BioTel Research
- Geneva Healthcare
- On.Demand
Products and services
- MCOT (Mobile Cardiac Outpatient Telemetry) MCOT is BioTelemetry's flagship mobile cardiac telemetry system for continuous arrhythmia detection and monitoring. Patients wear a small, lightweight, water-resistant patch that captures two channels of ECG data for up to 30 days. The SmartDetect AI algorithm processes data in real time and delivers urgent/emergent, daily, and end-of-service reports reviewed by cardiac technicians, enabling rapid diagnosis of atrial fibrillation and other arrhythmias.
- ePatch (Extended Holter) ePatch is Philips' extended Holter monitoring solution providing 3-14 days of continuous ECG recording with 99% patient compliance. Powered by Philips' medical-grade AI, it delivers actionable reports within 24 hours of upload, supporting arrhythmia detection, AF burden quantification, and ectopic beat analysis. Features flexible wear options (patch, FLEX electrode, lead wire) and EMR integration.
- Remote INR Patient Self-Testing Remote INR is BioTelemetry's INR (International Normalized Ratio) patient self-testing platform enabling warfarin patients to test their blood clotting levels at home using a CoaguChek Vantus device. Results are transmitted via a mobile app (Bluetooth), online portal, or automated phone system, with healthcare providers receiving real-time reports to adjust medication dosing. The service supports patient self-testing enrollment, compliance tracking, and 24/7 support.
- Geneva Healthcare Platform Cloud-based vendor-neutral remote monitoring platform for implantable cardiac device data management acquired by BioTelemetry in March 2019. Integrates with scheduling and DFT (Device Follow-Up) tracking for managing pacemaker and defibrillator patients. Protected by U.S. Patent Nos. 10,679,739 and D763879.
- On.Demand Remote Patient Monitoring Platform On.Demand is a chronic RPM and coaching platform acquired by BioTelemetry from Centene subsidiary Envolve People Care in July 2020. The platform provides chronic RPM and coaching for diabetes, hypertension, and chronic heart failure, combining real-time biometric monitoring with cellular- and web-based technology, proactive/reactive health coaching, population health reporting, and customizable interventions including Alexa Skill integration.
- LUX-Dx Insertable Cardiac Monitor (ICM) (Sales Agent) BioTelemetry serves as a sales agent in the United States for the Boston Scientific LUX-Dx Insertable Cardiac Monitor (ICM) System, the first ICM device with remote programming capability and a dual-stage arrhythmia detection algorithm. This adds an implantable cardiac monitor option to BioTelemetry's device portfolio of Holter, Extended Holter, Event monitors, and MCOT.
- BioTel Research (Centralized Core Laboratory) BioTelemetry's centralized core laboratory services for clinical trials, providing testing services for pharmaceutical and medical device clinical research. Supported by proprietary patents (U.S. Patent Nos. 6,731,782; 6,801,646; 6,836,557; 6,950,544; 7,103,224; 7,233,687; 7,346,201; 7,406,211; 6,664,893; 7,002,468; 8,425,414; 9,474,445).
- BioTel Heart (Unified Cardiac Monitoring Services) Consolidated service brand (launched in 2018) combining BioTelemetry's remote cardiac monitoring services including MCOT, ePatch, event monitors, Holter, and implantable device monitoring under the unified BioTel Heart brand, now integrated into Philips Ambulatory Monitoring and Diagnostics.
Quantifiable outcome
- MCOT detected AF in 23% of cryptogenic stroke patients (single center study)
- +4 more outcomes
Companies that use BioTelemetry
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
BioTelemetry technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability7 records
Feature5 records
BioTelemetry partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Boston ScientificcoreSales agent agreement for LUX-Dx Insertable Cardiac Monitor (ICM) System. BioTelemetry became sales agent in the US for the first ICM device with remote programming and dual-stage arrhythmia detection algorithm. Expands device portfolio beyond Holter, Extended Holter, Event monitors, and MCOT.
- Centene CorporationcoreAcquisition of On.Demand remote patient monitoring platform from Centene subsidiary Envolve People Care. BioTelemetry became exclusive provider of diabetes RPM services to Centene Medicaid members. Platform adds chronic RPM and coaching for diabetes, hypertension, and chronic heart failure.
- RochecoreBioTelemetry assumed responsibility to service Roche's remote INR patient base, expanding their Remote INR monitoring services.
- SprintminorJoint recipient of 2017 IoT Evolution Business Impact Award for IoT impact in healthcare remote monitoring.
- Giving it Back to KidsminorNon-profit partnership providing life-saving surgeries and medical care for children with heart disease in Southeast Asia. Heart for Hope program has completed over 740 heart surgeries.
- Hoan My HospitalminorVietnam hospital partnership for outreach program connecting patients to Heart for Hope program for congenital heart disease treatment.
- IMEC and Deltaminor2013 partnership to develop next generation cardiac monitoring products.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
BioTelemetry competitors and assessment
Company assessmentDirect peers
- iRhythm Technologies: iRhythm's Zio suite is a direct competitor in ambulatory cardiac monitoring, offering extended-wear patch Holter and MCT services to cardiology and primary care accounts. Both companies compete on diagnostic yield, wear time, AI-powered reporting, and EMR-integrated workflows for arrhythmia detection.
- AliveCor: AliveCor's KardiaMobile ECG devices and KardiaCloud platform provide patient- and provider-facing single-lead ECG and remote cardiac monitoring. It directly overlaps with BioTelemetry's primary care screening and arrhythmia detection use cases, especially at the lower-acuity end of the ambulatory ECG market.
Broad incumbents
- Boston Scientific: Boston Scientific is both a channel partner (LUX-Dx ICM sales agent agreement) and a broader incumbent in cardiac diagnostics and implantable cardiac devices. Its ICM and electrophysiology portfolio competes with Geneva's implantable device platform while its CRM franchise competes more broadly in cardiac care.
- Medtronic: Medtronic's Cardiac Rhythm Management franchise competes in implantable cardiac monitors (Reveal LINQ), diagnostics, and remote monitoring services through its CareLink network. It is a broad incumbent with overlapping implantable and ambulatory cardiac monitoring capabilities.
- GE Healthcare (incl. Muse): GE Healthcare's Muse is one of the dominant in-hospital ECG management systems and an integration partner for BioTelemetry. As a broader incumbent in diagnostic cardiology, it competes across inpatient and adjacent ambulatory ECG workflows.
- Koninklijke Philips (Royal Philips): Royal Philips is the parent company of BioTelemetry following the 2021 acquisition. Philips' broader Connected Care and Diagnostic Imaging businesses (IntelliSpace ECG, patient monitoring) provide the in-hospital counterpart to BioTelemetry's outpatient cardiac monitoring portfolio.
- Abbott: Abbott's cardiovascular portfolio includes insertable cardiac monitors (Confirm Rx), diagnostics, and remote monitoring. It is a broad incumbent in cardiac care whose implantable and ambulatory monitoring assets overlap with BioTelemetry's franchise.
Emerging players
- HeartBeam: HeartBeam is an emerging player developing a credit-card-sized 3D vector ECG platform for at-home and ambulatory cardiac diagnostics. Its technology focuses on synthesizing a 12-lead equivalent from a portable device — adjacent to BioTelemetry's ambulatory ECG franchise.
- InfoBionic: InfoBionic offers a cloud-based remote cardiac telemetry platform (MoMe ARC) for ambulatory arrhythmia monitoring and reporting. As an emerging niche player, it competes with BioTelemetry's MCOT and ePatch services on AI-driven arrhythmia detection workflows.
Others
- Hillrom (Baxter) / Welch Allyn: Hillrom (now part of Baxter) and its Welch Allyn franchise provide adjacent ambulatory and primary care diagnostic devices used in cardiology workflows. They serve as an ecosystem/adjacent player rather than a direct ambulatory cardiac monitoring competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BioTelemetry social profiles
Digital presenceBioTelemetry compliance and trust
Trust signalCompliance2 records
BioTelemetry financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioTelemetry leadership team
Management profileNumber of profiles
Profiles7 records
BioTelemetry subsidiaries and ownership
Company hierarchySubsidiaries15 records
BioTelemetry funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioTelemetry M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioTelemetry
What does BioTelemetry do?
BioTelemetry delivers remote cardiac monitoring and diagnostics services through FDA-cleared wearable devices (MCOT patch and ePatch Extended Holter) that capture and transmit ECG data for AI-powered arrhythmia detection, supplemented by Remote INR self-testing for anticoagulation management, Geneva Healthcare's implantable device monitoring platform, and BioTel Research core lab services for clinical trials. Services are physician-prescribed, processed through centralized monitoring centers, and delivered into major EMR systems for healthcare providers.
Is BioTelemetry a public or private company?
BioTelemetry is a public company. It is classified as corporate owned and is currently acquired.
When was BioTelemetry founded?
BioTelemetry was founded in 1994. It employs 1,001 to 5,000 people.
Where is BioTelemetry based?
BioTelemetry is headquartered in Malvern, United States, in the North America region.
How does BioTelemetry make money?
Four revenue lines are on record. Remote Cardiac Monitoring Services are the primary driver. The others are centralized Core Laboratory Services, remote Blood Glucose Monitoring and original Equipment Manufacturing.
Who are BioTelemetry's main competitors?
Direct peers on record are iRhythm Technologies and AliveCor. Broad incumbents are Boston Scientific, Medtronic, GE Healthcare (incl. Muse), Koninklijke Philips (Royal Philips) and Abbott. Emerging players are HeartBeam and InfoBionic. Hillrom (Baxter) / Welch Allyn is listed as an others.
Does BioTelemetry have an API?
No public API is recorded for BioTelemetry.
What industry is BioTelemetry in?
BioTelemetry's product category is Remote Cardiac Diagnostics and Monitoring. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3841.